Blog
RSS FeedPosted by Michael Wonder on 19 Nov 2022
Novavax’s COVID-19 booster has been approved for adults, Health Canada says
17 November 2022 - Health Canada said Thursday it has approved the booster dose of Novavax‘s Nuvaxovid COVID-19 vaccine for ...
Posted by Michael Wonder on 17 Nov 2022
New COVID-19 vaccines for eligible Australians
15 November 2022 - The Australian Government has accepted a recommendation from the Australian Technical Advisory Group on Immunisation (ATAGI) on ...
Posted by Michael Wonder on 15 Nov 2022
This is how access to older antibiotics can be strengthened
14 November 2022 - Shortages in access to antibiotics can pose serious obstacles to responsible antibiotic treatment - and a survey ...
Posted by Michael Wonder on 15 Nov 2022
ATAGI recommendations on use of the Pfizer COVID-19 vaccine for children aged 6 months to 4 years
15 November 2022 - On 29 September 2022, the TGA provisionally approved Comirnaty (Pfizer) COVID-19 vaccine for use in children ...
Posted by Michael Wonder on 15 Nov 2022
ATAGI recommendations on use of the Pfizer bivalent (Original/Omicron BA.1) COVID-19 vaccine
15 November 2022 - On 27 October 2022, the TGA provisionally approved the Pfizer (Comirnaty) Bivalent Original/Omicron BA.1 vaccine (subsequently referred ...
Posted by Michael Wonder on 15 Nov 2022
ATAGI update on boosters following COVID-19 meeting on 11 November 2022
15 November 2022 - An update from the Australian Technical Advisory Group on Immunisation (ATAGI) following their meeting on 11 November ...
Posted by Michael Wonder on 15 Nov 2022
COVID-19 vaccine safety report (3 November 2022)
3 November 2022 - To 30 October 2022, the TGA has received 704 reports which have been assessed as likely to ...
Posted by Michael Wonder on 08 Nov 2022
New COVID-19 variant leads to increase in cases
8 November 2022 - A statement from Professor Paul Kelly, Australian Government Chief Medical Officer, on the increase in COVID-19 cases ...
Posted by Michael Wonder on 07 Nov 2022
The Australian Government is committed to ensuring the safety of those at risk of monkeypox and has been working closely with states, territories and key stakeholders to ensure a coordinated national response
7 November 2022 - The Australian Government is committed to ensuring the safety of those at risk of monkeypox and ...
Posted by Michael Wonder on 25 Oct 2022
PHARMAC considers funding meningococcal B vaccine to be part of childhood immunisations
26 October 2022 - PHARMAC today has announced a consultation on widening access to the meningococcal B vaccine (branded as Bexsero), ...
Posted by Michael Wonder on 24 Oct 2022
ATAGI recommendations for a booster dose of the paediatric Pfizer COVID-19 vaccine in children aged 5 to 11 years
24 October 2022 - Recommendations from the Australian Technical Advisory Group on Immunisation on Pfizer booster doses for children aged 5 ...
Posted by Michael Wonder on 20 Oct 2022
COVID-19 vaccine safety report (20 October 2022)
20 October 2022 - To 16 October 2022, the TGA has received 705 reports which have been assessed as likely to ...
Posted by Michael Wonder on 13 Oct 2022
Clarity around PHARMAC’s priority lists (October 2022)
13 October 2022 - In March 2022, PHARMAC released its first Pūahoaho (clarity) Report, containing the latest information about its ...
Posted by Michael Wonder on 10 Oct 2022
Monkeypox vaccine not expected in NZ until December as community spread confirmed
10 October 2022 - New Zealand now has community transmission of monkeypox, but a vaccine to protect those at highest ...
Posted by Michael Wonder on 07 Oct 2022
COVID-19 vaccine safety report (6 October 2022)
6 October 2022 - To 2 October 2022, the TGA has received 703 reports which have been assessed as likely to ...